COSMOS Pharmaceutical Corporation (TYO:3349)
Japan · Delayed Price · Currency is JPY 6,501.00
-85.00 (-1.29%)
Sep 11, 2026, 3:30 PM JST
COSMOS Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is June - May.
Millions JPY. Fiscal year is Jun - May.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
| 1,099,583 | 1,011,390 | 964,989 | 827,697 | 755,414 | |
Revenue Growth | 8.72% | 4.81% | 16.59% | 9.57% | 3.99% |
Cost of Revenue | 869,900 | 798,109 | 776,683 | 658,979 | 603,966 |
Gross Profit | 229,683 | 213,281 | 188,306 | 168,718 | 151,448 |
Selling, General & Admin | 164,687 | 152,430 | 138,536 | 122,807 | 107,756 |
Operating Expenses | 187,330 | 172,877 | 156,804 | 138,589 | 121,651 |
Operating Income | 42,353 | 40,404 | 31,502 | 30,129 | 29,797 |
Interest Expense | -581 | -254 | -99 | -51 | -52 |
Interest & Investment Income | 74 | 48 | 44 | 47 | 52 |
Other Non Operating Income (Expenses) | 2,767 | 2,961 | 2,852 | 2,960 | 3,063 |
EBT Excluding Unusual Items | 44,613 | 43,159 | 34,299 | 33,085 | 32,860 |
Gain (Loss) on Sale of Assets | - | - | 75 | - | 265 |
Asset Writedown | -231 | -508 | -1,010 | -113 | -70 |
Other Unusual Items | -165 | -280 | 355 | -200 | -8 |
Pretax Income | 44,217 | 42,371 | 33,719 | 32,772 | 33,047 |
Income Tax Expense | 12,171 | 11,393 | 9,265 | 8,975 | 9,892 |
Net Income | 32,046 | 30,978 | 24,454 | 23,797 | 23,155 |
Net Income to Common | 32,046 | 30,978 | 24,454 | 23,797 | 23,155 |
Net Income Growth | 3.45% | 26.68% | 2.76% | 2.77% | -14.73% |
Shares Outstanding (Basic) | 79 | 79 | 79 | 79 | 79 |
Shares Outstanding (Diluted) | 79 | 79 | 79 | 79 | 79 |
Shares Change | - | 0.02% | 0.05% | - | - |
EPS (Basic) | 404.33 | 390.85 | 308.61 | 300.48 | 292.37 |
EPS (Diluted) | 404.33 | 390.85 | 308.61 | 300.48 | 292.37 |
EPS Growth | 3.45% | 26.65% | 2.71% | 2.77% | -14.73% |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | May '26 May 31, 2026 | May '25 May 31, 2025 | May '24 May 31, 2024 | May '23 May 31, 2023 | May '22 May 31, 2022 |
Free Cash Flow | -11,672 | -859 | -635 | 7,798 | -11,303 |
Free Cash Flow Per Share | -147.27 | -10.84 | -8.01 | 98.46 | -142.72 |
Dividend Per Share | 82.000 | 70.000 | 60.000 | 50.000 | 40.000 |
Dividend Growth | 17.14% | 16.67% | 20.00% | 25.00% | 14.29% |
Gross Margin | 20.89% | 21.09% | 19.51% | 20.38% | 20.05% |
Operating Margin | 3.85% | 4.00% | 3.26% | 3.64% | 3.94% |
Profit Margin | 2.91% | 3.06% | 2.53% | 2.88% | 3.06% |
Free Cash Flow Margin | -1.06% | -0.08% | -0.07% | 0.94% | -1.50% |
EBITDA | 66,929 | 62,633 | 51,426 | 47,497 | 44,907 |
EBITDA Margin | 6.09% | 6.19% | 5.33% | 5.74% | 5.95% |
D&A For EBITDA | 24,576 | 22,229 | 19,924 | 17,368 | 15,110 |
EBIT | 42,353 | 40,404 | 31,502 | 30,129 | 29,797 |
EBIT Margin | 3.85% | 4.00% | 3.26% | 3.64% | 3.94% |
Effective Tax Rate | 27.53% | 26.89% | 27.48% | 27.39% | 29.93% |
Advertising Expenses | 2,064 | 1,561 | 1,812 | 1,648 | 1,632 |